BrightSpring: $12.9 Billion in Revenue — and $2.30 of Profit per $100

There is an investor trap that springs shut whenever a number is genuinely large: the checkout-belt trap. You see $12.9 billion of revenue, mentally attach a margin you consider normal, and arrive at a profit that never existed. Tens of thousands of dollars cross a supermarket checkout belt every day. Almost none of it stays in the till, because nearly all of it was the purchase price of the goods. That is exactly how BrightSpring Health Services, Inc. (Nasdaq: BTSG) works. So let us make a deal: before we talk about growth, we work out together what a revenue dollar actually leaves behind — using only what the company filed with the U.S. securities regulator, the SEC. A filing is honest under penalty of law. We use the annual report (10-K) for 2025, filed February 27, 2026, and the quarterly report (10-Q) as of March 31, 2026, filed May 1, 2026.

What BrightSpring actually does — a pharmacy with a care business attached

BrightSpring looks after people where they live: at home, in senior living, in skilled nursing facilities. It is headquartered in Louisville, Kentucky, and as of December 31, 2025, it employed more than 23,500 full-time equivalents, roughly 3,500 of them represented by labor unions. Jon Rousseau runs the company as chairman, president and chief executive.

There are two reportable segments. Pharmacy Solutions is a pharmacy at industrial scale: home infusion therapy, specialty medicines for cancer and rare diseases, daily medication management for seniors and nursing homes. More than 43 million prescriptions were filled in 2025, out of over 175 pharmacies, infusion centers and specialty oncology locations across all 50 states. Provider Services is the care arm: home health, hospice, rehab therapy, home-based primary care. Together, BrightSpring says it serves roughly 465,000 patients at any one time, about 330,000 of them in their own homes.

Now the ratio that explains everything that follows. In the first quarter of 2026 the pharmacy produced $3,171.3 million of revenue and the care business $442.4 million. That is 87.8 percent against 12.2 percent. Arithmetically, BrightSpring is drug logistics with a care business attached — and drug logistics is a trade in which the purchase price of the goods eats almost the entire top line.

That names the central tension of this analysis, and it runs through every chapter: BrightSpring is growing at double-digit rates and has cut its debt burden visibly — but the faster it grows, the thinner its margin gets, because the growth comes from passing expensive medicines through. How differently a U.S. health care provider can look when the government also pays most of the bills shows up in our Encompass Health analysis, where a similar reimbursement dependence sits on top of an entirely different cost structure.

One 2026 event belongs here right away, otherwise the prior-year figures confuse: on March 30, 2026, BrightSpring sold its Community Living business — residential and support services for people with intellectual and developmental disabilities — to National Mentor Holdings for $835.0 million, with $810.9 million actually received. Every revenue and earnings figure in this analysis is therefore from continuing operations, computed the same way for every year.

Where the stock showed up in our scanner

The hook is not a headline but a balance sheet screen. Our in-house stock scanner lists BrightSpring on the U.S. side of its fundamental ranking — the list that sorts companies by the quality of their numbers rather than by their chart (as of July 26, 2026; the lists are recalculated daily). On the same date the list carries 38 U.S. names. You can replicate it in three clicks: open the stock scanner, pick the “Fundamental Rank (A / A+)” list, set the market to the United States.

The confluence is what stands out. On July 26, 2026, BTSG appeared on 25 of our scanner lists at once, and the selection reads like a cross-section of every school of thought: quality growth and institutional accumulation on the fundamental side; William O’Neil (CAN SLIM), Ben Bennett: Power Screen, Stan Weinstein: Stage 2 and Gary Antonacci: Dual Momentum on the trend side, plus the all-time-high list. When a stock reads as solid, accelerating and trending at the same time, it is worth a second look. That is what we are doing.

Two metrics from the July 24, 2026, data cut-off belong here, and both get rated, not just listed. The stock stood 196.9 percent above its level twelve months earlier — which is why so many trend lists fire, and also a reason for caution: a share price that has nearly tripled forgives no disappointment. And the equity ratio of 31.9 percent sounds unremarkable at first. It is not, once you know what that equity is made of. More on that shortly.

The numbers over the years — honestly appraised

First what genuinely impresses. Revenue rose to $12,910.6 million in 2025 — up 28.2 percent on the $10,072.2 million of 2024 and the $7,691.0 million of 2023. That is 68 percent in two years. And 2025 was the first profitable year in a while: $190.7 million was attributable to shareholders, or $0.94 per share, after losses of $18.1 million in 2024 and $154.6 million in 2023.

The jump in actual cash is even sharper. Operating cash flow came in at $490.2 million in 2025 — after $23.8 million the year before. That is not window dressing but mostly lower interest and better operating income. Adjusted EBITDA, the earnings measure before interest, taxes and depreciation, rose 34.2 percent to $617.6 million.

And here is the finest number in this analysis, because it marks a turn:

Remember this one: at BrightSpring the turn did not happen in revenue, it happened in the interest line. In 2023 the company paid $271.9 million of net interest on $58.1 million of operating income — it was working for its lenders. In 2025, $157.3 million of interest stood against $295.3 million of operating income. Interest is now covered nearly twice over.

The start of 2026 continued the run. First-quarter revenue climbed to $3,613.7 million from $2,878.1 million a year earlier (up 25.6 percent), and operating income to $121.4 million from $50.7 million. The bottom line was $148.8 million — but $74.3 million of that came from the divested Community Living business. Continuing operations contributed $74.4 million.

And leverage as measured by the credit agreement fell in a single quarter from 2.99x to 2.27x, helped by the sale proceeds that lifted cash from $88.4 million on December 31, 2025, to $888.8 million on March 31, 2026. That is the good half of the story, and it is real.

What the filings say — the uncomfortable truths

Uncomfortable truth no. 1: of every $100 in revenue, $2.30 is left

Let us run the checkout-belt trap all the way through. Of the $12,910.6 million of 2025 revenue, $10,507.4 million went to cost of goods — essentially the purchase price of the medicines BrightSpring delivers. Another $885.4 million was the cost of services rendered and $1,222.5 million selling, general and administrative expense. What was left was $295.3 million of operating income.

In everyday terms: this is not a restaurant, it is a delivery service. And the unpleasant part is in the time series. Gross margin — what is left after the pure cost of the goods — was 14.8 percent of revenue in 2023, 12.6 percent in 2024 and only 11.8 percent in 2025. The faster BrightSpring grows, the thinner the slice, because the growth comes mostly from expensive specialty medicines on which a pharmacy earns only a small markup.

Fairness requires the other side. In the first quarter of 2026 gross margin recovered to 13.3 percent from 11.8 percent a year earlier, and pharmacy segment EBITDA grew 46.1 percent against segment revenue growth of 25.2 percent. One quarter is not a trend — but it is the first one pointing the other way.

Uncomfortable truth no. 2: strip out goodwill and the equity is gone

The balance sheet as of March 31, 2026, reports total equity of $1,979.4 million, or 31.9 percent of total assets of $6,213.3 million. That sounds respectable. Now look at what it is made of. The asset side carries $2,533.6 million of goodwill — the amount BrightSpring paid in acquisitions above the value of the assets it took over — plus another $536.9 million of other intangibles such as customer relationships and licenses.

Deduct goodwill alone from equity and you are left with negative $554.2 million. Add the other intangibles and it is negative $1,091.1 million. In everyday terms: the house is paid off, but half the purchase price was the view. Goodwill is neither fraud nor an accounting error — it is the residue of the buyouts through which KKR and Walgreens Boots Alliance acquired PharMerica in 2017 and BrightSpring Health Holdings in 2019. But it generates no cash and disappears instantly in an impairment.

Then there is the other side of the balance sheet. The 2025 annual report names its own debt load in the risk factors:

"As of December 31, 2025, we had approximately $2,521.3 million outstanding under the First Lien Term Loan Facility. As of December 31, 2025, we had $475.0 million of borrowing capacity available under the Revolver as there were no borrowings under the Revolver or letters of credit outstanding, and $62.8 million of letters of credit outstanding under the LC Facility."

— BrightSpring Health Services, Inc., annual report 10-K for 2025, Item 1A Risk Factors

The loan — the Tranche B-5 term loan of originally $2,553.2 million, established December 11, 2024 — carries a floating rate of SOFR plus 2.50 percent and matures on February 21, 2031. Until then only 0.25 percent of the original principal amortizes each quarter; the rest sits in a balloon payment. Two things belong on the credit side: the $475.0 million revolver is undrawn, and leverage of 2.27x as of March 31, 2026, is not critical. But floating rate also means that a rising rate raises the bill.

Uncomfortable truth no. 3: government pays more than two-thirds of the revenue

The quarterly report as of March 31, 2026, breaks revenue down by payor, and the picture is unambiguous. 68.5 percent of group revenue in the first quarter of 2026 came from government programs: Medicare Part D (the drug benefit) alone 29.7 percent, Part C (Medicare Advantage) 18.5 percent, Medicaid 11.2 percent, Part A 8.5 percent and Part B 0.6 percent. Commercial insurers accounted for 28.0 percent, private and other payors for 3.5 percent.

BrightSpring puts it in a single sentence:

"The Company is substantially dependent on revenues received under contracts with federal, state, and local government agencies."

— BrightSpring Health Services, Inc., quarterly report 10-Q as of March 31, 2026, note 3 (Revenue)

Why this weighs more heavily here than elsewhere: at a 2.29 percent operating margin, a two-point cut in reimbursement rates is enough to erase the entire result. The annual report lists the risks at length — federal budget cuts, state budget shortfalls, changing pricing benchmarks for generics. Then there is the enforcement pressure: the 2025 annual report discloses an ongoing investigation by the Department of Justice and the Drug Enforcement Administration into the company’s own Embrace Hospice business over services that may not have been reasonable and medically necessary. No outcome has been reached and no amount is quantified — but it shows how tightly this business is bound to the rulebook.

Uncomfortable truth no. 4: the former owner is selling into strength

KKR built BrightSpring, took it public in January 2024 — and sold big twice within three months in 2026. On March 4, 2026, 20,000,000 shares were placed; the company bought 1,464,807 of them back at $40.96 for $60.0 million. On June 3, 2026, another 14,999,771 shares followed at a public offering price of $58.75.

The movement behind it: before the June placement KKR held 41,824,259 shares, or 21.2 percent of the voting power, and afterwards, per ownership filing SC 13D/A no. 5, 26,829,880 shares, or 13.6 percent. Directors, officers and affiliates together fell from 56.1 percent to 48.7 percent — the majority is gone. Selling alongside were chief executive Jon Rousseau (260,000 shares), chief financial officer Jennifer Phipps (35,000) and chief of staff Lisa Nalley (35,000).

This is expressly not a scandal. A financial sponsor exits eventually; that is the business model, and a shrinking overhang is better for remaining shareholders than a growing one. The timing is what is interesting. The June 2025 base prospectus reports a last sale price of $23.86 (as of June 9, 2025). The sales came nine and twelve months later at $40.96 and $58.75. The people who know the company best sold into strength. The agreed 45-day lock-up expired on July 18, 2026.

Uncomfortable truth no. 5: on February 1, 2027, roughly 11.7 million shares appear

A second security trades on Nasdaq alongside the stock: BTSGU, the 6.75 percent tangible equity units. Exactly 8,000,000 of them were issued at $50.00 each alongside the 2024 IPO. Each unit combines an amortizing note with a prepaid stock purchase contract. That contract settles into shares on a fixed date:

Let us do the arithmetic together. The 2025 annual report gives the minimum settlement rate of 3.2733 shares per unit and discloses that holders converted 31,211 units early in 2024 and another 4,384,020 in 2025; per the quarterly report, none at all were converted in the first quarter of 2026. That leaves 3,584,769 units — times 3.2733 equals roughly 11.7 million new shares, close to 6 percent of the 196,588,412 shares most recently reported. No new money arrives; the buyers paid in 2024.

The catch for anyone reading per-share metrics: those shares are already in the income statement. BrightSpring computed the first quarter of 2026 on a basic share count of 204.7 million and a diluted count of 221.3 million — while the balance sheet cover page for the same date shows only 193,209,722 shares. Take the smaller number and recompute earnings per share, and the answer comes out too flattering. In everyday terms: the cake is already cut into more slices than the plate shows.

What the stock costs

For valuation we deliberately use numbers that appear in documents rather than a daily quote. The prospectus supplement dated June 5, 2026, reports 196,588,412 shares after the offering and repurchase, and a closing price of $57.40 on June 4, 2026. That works out to a market value of roughly $11.3 billion.

That is 0.9 times 2025 revenue — an ordinary order of magnitude for a drug logistics business, precisely because most of the top line is pass-through goods. The earnings multiples say more: 59 times 2025 net income of $190.7 million and, after adding debt and deducting cash, roughly 21 times adjusted EBITDA of $617.6 million. For a business running a 2.29 percent operating margin, that is not a bargain price.

The fundamental data as of July 24, 2026, sit higher, because the share price kept climbing between early June and late July: price/earnings ratio 89.6, forward price/earnings ratio on current-year estimates 38.3, price/sales 1.01, price/book 6.8, enterprise value to EBITDA 29.4. On that date the stock stood 196.9 percent above its level twelve months earlier.

The professionals’ view is strikingly sober. As of July 24, 2026, the mean price target from 12 analysts was $67. The stock itself closed that day at $72.91 — so the target sat roughly 8 percent below it. Measured against the documented June 4, 2026, closing price of $57.40, from which we calculate the market value above, the very same $67 sits roughly 17 percent above. Put differently: analysts like the company and consider the price it ran to by late July full. At the same time, 7.46 percent of the free float was sold short. BrightSpring pays no dividend.

Opportunities and risks at a glance

What speaks for BrightSpring:

• A market with demographic tailwind: care at home is cheaper than care in hospital, and the number of very old patients keeps rising. BrightSpring serves roughly 465,000 patients at any one time.
• Revenue grew 68 percent in two years to $12,910.6 million in 2025, and another 25.6 percent in the first quarter of 2026 — organically and through acquisitions such as the Amedisys and LHC branches taken over in 2025.
• An interest turn inside the company: in 2025 operating income of $295.3 million clearly exceeded interest expense of $157.3 million, and operating cash flow jumped to $490.2 million from $23.8 million.
• Leverage under the credit agreement fell within one quarter from 2.99x to 2.27x, cash rose to $888.8 million, and the $475.0 million revolver is undrawn.
• The overhang is shrinking: KKR is down from 21.2 percent to 13.6 percent, and the free float stands at roughly 90 percent.

What speaks against it:

• A 2.29 percent operating margin leaves no room for error. Of every $100 in revenue, $81.40 is the purchase price of the goods.
• Gross margin fell from 14.8 percent in 2023 to 11.8 percent in 2025 — growth and margin are pulling in opposite directions.
• $2,497.8 million of financial debt as of March 31, 2026, floating rate, with a balloon payment in 2031; equity of $1,979.4 million is exceeded by goodwill of $2,533.6 million.
• 68.5 percent of revenue depends on Medicare and Medicaid, and the company calls itself substantially dependent on government contracts. An investigation into the Embrace Hospice business is open.
• Roughly 11.7 million shares arrive on February 1, 2027, out of the tangible equity units, on top of 13,087,872 options and 6,223,627 restricted stock units (as of June 2, 2026).
• The share price nearly tripled in twelve months (data as of July 24, 2026) — and the mean analyst price target sat below it.

A human conclusion

Back to the checkout-belt trap. It does not spring shut because anyone is lying — BrightSpring discloses every one of these numbers, in tables you can look up. It springs shut because our minds automatically attach a margin to large numbers that this business never had. $12.9 billion sounds like a company that prints money. In fact BrightSpring earns $2.30 on every $100 of revenue, before interest and taxes.

That does not make it a bad company. It makes it something other than what the top line suggests: a volume business in which the craft lies not in pricing but in purchasing, in logistics, and in getting along permanently with one very large payor — the government. If that appeals to you, here is a company with genuine tailwind, falling debt and a market that is not going away. If you prefer companies where a bad quarter has room inside the margin, there is little cushion here.

You have now done that check yourself, with the original documents on the table. What you make of it is your decision. And that is exactly as it should be.

Sources

Every original document used in this analysis, for you to read yourself:

• BrightSpring Health Services, Inc. — quarterly report 10-Q as of March 31, 2026 (filed May 1, 2026)
• BrightSpring Health Services, Inc. — annual report 10-K for 2025 (filed February 27, 2026)
• BrightSpring Health Services, Inc. — annual report 10-K for 2024 (filed March 6, 2025)
• BrightSpring Health Services, Inc. — current report 8-K dated June 3, 2026 (offering by KKR and management), plus the current report 8-K dated June 11, 2026 (appointment of Dr. Nigam H. Shah to the board)
• BrightSpring Health Services, Inc. — prospectus supplement 424B7 dated June 5, 2026 (share count, prices, ownership)
• KKR Phoenix Aggregator L.P. and others — ownership filing SC 13D/A no. 5 dated June 5, 2026, and all other filings: EDGAR overview for CIK 0001865782 (sec.gov)
• Fundamental data (metrics, valuation, analyst estimates; data as of July 24, 2026), reconciled with the SEC filings.
• Scanner lists: our in-house stock scanner, as of July 26, 2026; the lists are recalculated daily.

Transparency & disclaimer: this analysis is journalistic commentary on publicly available information. It is not investment advice, not a regulated financial analysis and not a solicitation to buy or sell securities. Equity investments carry substantial risk up to total loss. All figures are provided without warranty; the as-of date is noted in the text. The author holds no position in BrightSpring shares at the time of publication.